JP2017508469A - 癌悪性度、予後及び治療に対する反応性の決定 - Google Patents

癌悪性度、予後及び治療に対する反応性の決定 Download PDF

Info

Publication number
JP2017508469A
JP2017508469A JP2016556734A JP2016556734A JP2017508469A JP 2017508469 A JP2017508469 A JP 2017508469A JP 2016556734 A JP2016556734 A JP 2016556734A JP 2016556734 A JP2016556734 A JP 2016556734A JP 2017508469 A JP2017508469 A JP 2017508469A
Authority
JP
Japan
Prior art keywords
genes
expression level
cancer
underexpressed
overexpressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508469A5 (https=
Inventor
アル−エジェ、ファレス
Original Assignee
ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900813A external-priority patent/AU2014900813A0/en
Application filed by ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ filed Critical ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Publication of JP2017508469A publication Critical patent/JP2017508469A/ja
Publication of JP2017508469A5 publication Critical patent/JP2017508469A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016556734A 2014-03-11 2015-03-11 癌悪性度、予後及び治療に対する反応性の決定 Pending JP2017508469A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014900813A AU2014900813A0 (en) 2014-03-11 Determining cancer agressiveness, prognosis and responsiveness to treatment
AU2014900813 2014-03-11
AU2014901212 2014-04-03
AU2014901212A AU2014901212A0 (en) 2014-04-03 Determining cancer agressiveness, prognosis and responsiveness to treatment
AU2014904716 2014-11-21
AU2014904716A AU2014904716A0 (en) 2014-11-21 Determining cancer agressiveness, prognosis and responsiveness to treatment
PCT/AU2015/050096 WO2015135035A2 (en) 2014-03-11 2015-03-11 Determining cancer agressiveness, prognosis and responsiveness to treatment

Publications (2)

Publication Number Publication Date
JP2017508469A true JP2017508469A (ja) 2017-03-30
JP2017508469A5 JP2017508469A5 (https=) 2018-03-29

Family

ID=54072534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556734A Pending JP2017508469A (ja) 2014-03-11 2015-03-11 癌悪性度、予後及び治療に対する反応性の決定

Country Status (11)

Country Link
US (1) US20170107577A1 (https=)
EP (1) EP3119908A4 (https=)
JP (1) JP2017508469A (https=)
KR (1) KR20160132067A (https=)
CN (1) CN106661614A (https=)
AU (1) AU2015230677A1 (https=)
BR (1) BR112016020897A2 (https=)
CA (1) CA2941769A1 (https=)
MX (1) MX2016011612A (https=)
SG (2) SG11201607448PA (https=)
WO (1) WO2015135035A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021015084A1 (ja) * 2019-07-19 2021-01-28 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
JP2024029038A (ja) * 2017-06-13 2024-03-05 ボストンジーン コーポレイション 分子機能プロファイルを生成、視覚化、及び分類するためのシステム及び方法

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP3143160B1 (en) * 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3377646A1 (en) * 2015-11-20 2018-09-26 Université de Strasbourg Method for identifying personalized therapeutic strategies for patients affected with a cancer
EP4715067A2 (en) * 2015-11-20 2026-03-25 Université de Strasbourg Method for identifying personalized therapeutic strategies for patients affected with a cancer
MX2018009368A (es) * 2016-02-01 2018-09-05 Bayer Pharma AG Biomarcadores para copanlisib.
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
WO2018029586A1 (en) * 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US11672801B2 (en) 2016-10-19 2023-06-13 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
WO2018152585A1 (en) * 2017-02-23 2018-08-30 The Council Of The Queensland Institute Of Medical Research "biomarkers for diagnosing conditions"
WO2018161081A1 (en) * 2017-03-03 2018-09-07 Board Of Regents, The University Of Texas System Gene signatures to predict drug response in cancer
CN110678928A (zh) * 2017-03-28 2020-01-10 南托米克斯有限责任公司 使用PARADIGM对miRNA诱导的乳腺癌中的沉默进行建模
WO2018177326A1 (en) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) System and method for determining karenitecin sensitivity on cancer
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
US10854338B2 (en) * 2017-03-29 2020-12-01 Imaging Endpoints II LLC Predicting breast cancer responsiveness to hormone treatment using quantitative textural analysis
EP3606518A4 (en) * 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
JP2020524169A (ja) * 2017-06-20 2020-08-13 ジ・インスティチュート・オブ・キャンサー・リサーチ：ロイヤル・キャンサー・ホスピタル 方法および医学的利用
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
SG11202000132WA (en) * 2017-07-10 2020-02-27 Univ Cornell Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
EP3695408B1 (en) * 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
CN107868825A (zh) * 2017-11-21 2018-04-03 山东省千佛山医院 一种诊治肺腺癌的分子标记物
US11851712B2 (en) 2018-03-06 2023-12-26 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
JP2021522848A (ja) * 2018-05-15 2021-09-02 オンコロジー ベンチャー アーペーエス 癌患者における薬物応答性を予測する方法
CN108704135A (zh) * 2018-05-24 2018-10-26 江苏大学附属医院 Chaf1a抑制剂在制备胃癌治疗药物中的用途
CN108866189B (zh) * 2018-07-12 2022-03-01 吉林大学 一种喉鳞状细胞癌易感性预测试剂盒及系统
CN108841959B (zh) * 2018-07-12 2022-03-01 吉林大学 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统
CN108949984B (zh) * 2018-07-25 2022-01-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 基因desi2在三阴乳腺癌诊断、预后评估及治疗中的应用
CN109593771B (zh) * 2018-07-27 2022-03-29 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN110787296B (zh) * 2018-08-01 2024-04-16 复旦大学附属肿瘤医院 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer
CN110286219A (zh) * 2019-04-16 2019-09-27 福建师范大学 死亡相关蛋白激酶1在制备肾透明细胞癌术后预后评估试剂盒中的应用
CN111370056B (zh) * 2019-05-22 2021-03-30 深圳思勤医疗科技有限公司 确定待测样本预定染色体不稳定指数的方法、系统和计算机可读介质
US11715565B2 (en) * 2019-11-08 2023-08-01 Tempus Labs, Inc. Evaluating effect of event on condition using propensity scoring
EP4106879A4 (en) * 2020-02-19 2024-02-21 United States Government as Represented by The Department of Veterans Affairs IDENTIFICATION OF AN EGFR-BIN3 PATHWAY FOR ACTIVE SUPPRESSION OF INVASION AND REDUCTION OF TUMOR SIZE IN GLIOBLASTOMA
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
WO2022011425A1 (en) * 2020-07-15 2022-01-20 Queensland University Of Technology Determining cancer responsiveness to treatment
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
CA3192695A1 (en) * 2020-09-16 2022-03-24 Novigenix Sa Biomarkers for immune checkpoint inhibitors treatment
CN112111575B (zh) * 2020-09-22 2023-01-10 重庆医科大学附属第一医院 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用
GB2628478A (en) 2020-10-29 2024-09-25 Ambergen Inc Novel photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes
JP7830464B2 (ja) * 2020-11-23 2026-03-16 サノフイ 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル
CA3196872A1 (en) * 2020-12-23 2022-06-30 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t cells
WO2022217060A1 (en) * 2021-04-09 2022-10-13 Cardiff Oncology, Inc. Cancer treatment using parp inhibitors and plk1 inhibitors
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
CN113355419B (zh) * 2021-06-28 2022-02-18 广州中医药大学(广州中医药研究院) 一种乳腺癌预后风险预测标志组合物及应用
CN113502329A (zh) * 2021-07-12 2021-10-15 隋雨桐 检测腺苷受体a2b表达量的试剂在制备肺腺癌的诊断和/或预后试剂盒中的应用
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
CN114540500A (zh) * 2022-03-21 2022-05-27 深圳市陆为生物技术有限公司 评价乳腺癌患者整体生存的产品
CN115369173A (zh) * 2022-09-23 2022-11-22 河北医科大学第三医院 基因标志物组合在预测膀胱尿路上皮癌预后中的应用
EP4494152A4 (en) 2023-06-09 2025-10-08 Seekin Inc Shenzhen China METHODS FOR DETECTING CANCER
CN119913252A (zh) * 2023-10-31 2025-05-02 南京安吉生物科技有限公司 Gemin4基因及Gemin4蛋白在肿瘤中的应用
CN120290720B (zh) * 2025-04-11 2025-12-23 新疆医科大学第三附属医院 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
CN120594831B (zh) * 2025-05-30 2026-03-13 南方医科大学南方医院 细胞外囊泡膜蛋白在制备早期胃癌诊断试剂盒中的应用
CN120536581B (zh) * 2025-06-19 2026-04-17 十堰市太和医院（湖北医药学院附属医院） Ul16结合蛋⽩2作为结直肠癌标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
JP2007528218A (ja) * 2004-02-20 2007-10-11 ベリデックス・エルエルシー 乳癌の予後診断

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320443T3 (es) * 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
BRPI0716391A2 (pt) * 2006-09-05 2017-01-31 Veridex Llc método de previsão de metástase distante de câncer de mama primário nódulo linfático-negativo usando análise de expressão gênica de via biloógica
US8273534B2 (en) * 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
WO2010129965A1 (en) * 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
WO2013163134A2 (en) * 2012-04-23 2013-10-31 The Trustees Of Columbia University In The City Of New York Biomolecular events in cancer revealed by attractor metagenes
US9863935B2 (en) * 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528218A (ja) * 2004-02-20 2007-10-11 ベリデックス・エルエルシー 乳癌の予後診断
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024029038A (ja) * 2017-06-13 2024-03-05 ボストンジーン コーポレイション 分子機能プロファイルを生成、視覚化、及び分類するためのシステム及び方法
WO2021015084A1 (ja) * 2019-07-19 2021-01-28 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
JP2021016350A (ja) * 2019-07-19 2021-02-15 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
JP7352937B2 (ja) 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット

Also Published As

Publication number Publication date
KR20160132067A (ko) 2016-11-16
CA2941769A1 (en) 2015-09-17
AU2015230677A1 (en) 2016-10-27
US20170107577A1 (en) 2017-04-20
CN106661614A (zh) 2017-05-10
SG11201607448PA (en) 2016-10-28
WO2015135035A2 (en) 2015-09-17
EP3119908A2 (en) 2017-01-25
EP3119908A4 (en) 2018-02-21
MX2016011612A (es) 2016-12-12
WO2015135035A3 (en) 2016-09-15
SG10201807838SA (en) 2018-10-30
BR112016020897A2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
JP2017508469A (ja) 癌悪性度、予後及び治療に対する反応性の決定
Huang et al. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
Kohmoto et al. Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer
US11254986B2 (en) Gene signature for immune therapies in cancer
CN113025713A (zh) 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
US10280468B2 (en) Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
US20140155397A1 (en) Emt signatures and predictive markers and method of using the same
KR20110018930A (ko) 암 치료에서 예후적 및 예견적 마커의 확인 및 용도
US20110320392A1 (en) Methods for predicting cancer response to egfr inhibitors
Pellegrino et al. Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
KR102939030B1 (ko) 전이성 신장암 예후 예측용 신규 바이오마커 및 이의 용도
KR102403807B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
Qiu et al. Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis
Yang et al. BTLA promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma
Weng et al. Predicting bevacizumab efficacy: the emerging role of ACTL6B in colorectal cancer
US20220081727A1 (en) Biomarker for predicting response to anticancer agent and use thereof
Bai et al. A dynamic miRNA-mRNA network serves as a crosstalk between abnormal cell cycle and immunosuppressive microenvironment in the colorectal adenoma-carcinoma sequence
US20240158871A1 (en) Pan-Cancer Classification Based on FMRP Pathway Activity that Informs Differential Prognosis and Therapeutic Responses
Hergalant et al. Sebastien Hergalant1, Jean-Matthieu Casse1, Abderrahim Oussalah1, 2, 3, Remi Houlgatte1, Deborah Helle1, Fabien Rech4, 5, Laurent Vallar6, Jean-Louis Gueant1, 2, 3, Jean-Michel Vignaud1, 7, 8, Shyue-Fang Battaglia-Hsu2, 3, 5 and Guillaume Gauchotte1, 7, 8
Gong et al. Identification and validation of an m1A-score model to predict outcomes and immunomodulation in lung squamous cell carcinoma by integrated analysis of single-cell and bulk RNA sequencing
US20120100999A1 (en) Prognostic gene expression signature for squamous cell carcinoma of the lung
WO2023081190A1 (en) Epithelial-mesenchymal transition-based gene expression signature for kidney cancer
Shang et al. Blood Circulating miRNA Pairs as a Robust Signature for Early Detection
Ibrahim-zada Genetic variations associated with resistance to doxorubicin and paclitaxel in breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191008